| Identification | Back Directory | [Name]
Duvoglustat Hydrochloride | [CAS]
308362-25-6 | [Synonyms]
SMT19969
5,5'-Bi-1H-benzimidazole, 2,2'-di-4-pyridinyl-
2,2'-Di(pyridin-4-yl)-1H,1'H-5,5'-bibenzo[d]imidazole
2,2'-di(pyridin-4-yl)-3H,3'H-5,5'-bibenzo[d]imidazole | [Molecular Formula]
C24H16N6 | [MDL Number]
MFCD28963972 | [MOL File]
308362-25-6.mol | [Molecular Weight]
388.42 |
| Chemical Properties | Back Directory | [Boiling point ]
774.9±70.0 °C(Predicted) | [density ]
1.372±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 60 mg/mL (154.47 mM) | [form ]
Solid | [pka]
9.84±0.10(Predicted) | [color ]
Light yellow to yellow | [InChI]
InChI=1S/C24H16N6/c1-3-19-21(29-23(27-19)15-5-9-25-10-6-15)13-17(1)18-2-4-20-22(14-18)30-24(28-20)16-7-11-26-12-8-16/h1-14H,(H,27,29)(H,28,30) | [InChIKey]
UHQFBTAJFNVZIV-UHFFFAOYSA-N | [SMILES]
C1(C2C=CN=CC=2)NC2=CC=C(C3=CC=C4NC(C5C=CN=CC=5)=NC4=C3)C=C2N=1 |
| Hazard Information | Back Directory | [Uses]
Ridinilazole is a novel antibacterial with MICs range of 0.06-0.25?μg/mL (MIC90=8?μg/mL) against C.?difficile. | [in vivo]
In a hamster model of CDI with a once-daily dosing regimen, Ridinilazole displays greater efficacy than Vancomycin both against non-epidemic and epidemic strains of C.?difficile. Similar to the twice-daily dosing study, plasma levels of Ridinilazole are below the level of detection, whereas caecal Ridinilazole concentrations are well above the MIC, thus demonstrating the non-absorbable nature of Ridinilazole and minimal systemic exposure[1]. | [References]
[1] Vickers RJ, et al. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug;48(2):137-43. DOI:10.1016/j.ijantimicag.2016.04.026 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|